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a  b  s  t  r  a  c  t
Objective:  The  present  article  is  an update  of  the  guideline  of  the French  Society  of  Otorhinolaryngology
and Head  and  Neck  Surgery  (SFORL)  on  the post-treatment  follow-up  of  adult  head  and  neck  squa-
mous  cell  carcinoma  concerning  screening  for metastasis  and  metachronous  esophageal  and  bronchial
locations.
Methods:  A  multidisciplinary  work-group  was  entrusted  with  a review  of  the  literature  on  the  above  topic.
Guidelines  were  drawn  up,  based  on  the  articles  retrieved  and  the  work-group  members’  own  experience.
These were  then  reviewed  by an  editorial  group independent  of the work-group.  A coordination  meeting
then  ﬁnalized  the  guidelines.  Guidelines  were  graded  A,  B, C or “expert  opinion”  according  to  decreasing
level  of evidence.. Head and neck cancer and metachronous
ronchopulmonary and esophageal locations
Neoplasia is said to be metachronous with respect to a head and
eck tumor when diagnosed at least 6 months after the primary
iagnosis; earlier than this, it is said to be synchronous [1,2].
Patients managed for head and neck carcinoma are exposed to a
isk of locoregional recurrence and/or onset of second cancer. Two
eriods can be roughly distinguished:
the ﬁrst 2 or 3 years following primary treatment show elevated
risk of locoregional recurrence and metastasis;
thereafter, the risk of second (metachronous) cancer predom-
inates, mainly in the head and neck region but also remotely,
notably in the lung or esophagus [1,3].Risk of second cancer is higher in patients who continue active
moking and/or alcohol abuse after primary treatment [1]. This
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risk persists to a lesser extent after smoking cessation, with a high
rate of persistent high-grade precancerous lesions (severe dyspla-
sia, which in 40–80% of cases progresses toward an invasive lesion
or in situ carcinoma) found on bronchoscopy in patients who  have
given up smoking [4]. The risk is not to be taken into account in
those who  have never smoked [4].
The risk of metachronous cancer during follow-up of head and
neck cancer is well known [1–3,5–7], with an annual rate of 3–7%.
No correlation has been found between primary tumor stage
and rate of onset of metachronous cancer.
A laryngeal primary location increases the risk of bronchopul-
monary metachronous cancer [1], and oral or pharyngeal location
that of esophageal metachronous cancer.
Risk persists over time [6,7].
1.1. Bronchopulmonary metachronous locations
Three histologic types are found, in decreasing order of fre-
quency: squamous cell carcinoma, adenocarcinoma, and small-cell
carcinoma [8]. Squamous cell carcinoma accounts for 50–65% of
pulmonary metachronous cancers in males and 20–25% in females
[9]. Adenocarcinoma is more frequent in females than males [10].
















































                                                       Solid nodule
Entirely calcified solid nodule             Solid nodule >5mm and <10mm          nodule >10 mm     
with fat  de nsity  sit e 
Nodule <5mm                                          CT at 3 months                                 Specialist opinion 
CT in 1 year                   Specialist opinion in case of progression
mean age at onset of head and neck cancer plus mean time to onset
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More than 95% of lung cancers are discovered in the absence of
linical signs [3]. Squamous cell carcinoma is the most frequently
ymptomatic, due to anatomic location: central, para-hilar, major
ronchial axes [9]. This underscores the need for paraclinical exam-
nations in screening for such cancers.
.1.1. Role of biological markers
There are no validated biological markers in bronchopulmonary
ancer screening [11].
.1.2. Role of cytology
Bronchopulmonary cancer screening by cytological sputum
nalysis in high-risk populations is not considered contributive
11,12].
.1.3. Role of lung X-ray
In high-risk populations, the contribution of chest X-ray in bron-
hopulmonary cancer screening was the focus of several reports,
ncluding 2 prospective randomized studies [11,13]. Radiologic
creening was found to increase the rate of early-stage detection,
easibility of surgery and overall survival. This gain in survival, how-
ver, is dependent on discovery and diagnosis of slowly progressive
esions: no studies have reported reduction in mortality speciﬁc to
ung cancer.
These studies established that bronchial cancer screening by
hest X-ray in high-risk populations is non-contributive [11].
Several studies [7,14,15] focused on chest X-ray follow-up of
ead and neck cancer patients: none found improved survival in
atients screened for second bronchopulmonary cancer.
Head and neck cancer follow-up by routine iterative lung X-ray
as not proved contributive.
.1.4. Role of CT
CT screening for bronchopulmonary cancer in high-risk patients
hows high sensitivity but poor speciﬁcity. It enables early-stage
iagnosis, increases surgical feasibility, and increases survival in
atients screened for bronchopulmonary cancer by 20% at 5 years
16,17].
The rate of bronchopulmonary cancer found on screening is 0.7%
or chest X-ray and 2.7% for low-dose spiral CT [18].
A 2011 randomized trial including 53,454 smokers aged 55-74
ears with > 30 pack-years compared 3 years’ annual bronchopul-
onary cancer screening by chest X-ray versus low-dose CT
ithout contrast enhancement [19]; there was a signiﬁcant
0% reduction in death from bronchopulmonary cancer (95% CI:
.86–26.7; P = 0.004) and overall mortality (6.7%; 95% CI: 1.2–13.6;
 = 0.020) in the CT group. This was the ﬁrst study to show a sur-
ival impact of bronchopulmonary cancer screening in high-risk
atients.
A 2014 meta-analysis of 9 randomized studies conﬁrmed these
ndings [20].
These results led several international learned societies to rec-
mmend individual screening of bronchopulmonary cancer in
igh-risk subjects alongside anti-smoking campaigns [21–23].
All publications on low-dose CT bronchopulmonary cancer
creening report false positives in the form of non-cancerous nod-
les. In case of nodule discovered on chest CT, the work-group
ecommends the attitude shown on Figs. 1 and 2, following the
uidelines of the French-Language Thoracic Oncology Intergroup,
ociety of Thoracic Imaging and French-Language Oncology Group
24]..1.5. Role of autoﬂuorescence bronchoscopy
Screening and treatment of precancerous bronchial lesions
y autoﬂuorescence bronchoscopy has been the focus of several
tudies in high-risk subjects [25–28], with discordant ﬁndings.Fig. 1. Decision tree in case of isolated solid pulmonary nodule on CT.
Autoﬂuorescence improved detection and follow-up of precancer-
ous and in situ lesions, but the impact on speciﬁc mortality is not
known. The examination is not widely available, and in the present
state of knowledge is reserved to controlled assessment protocols.
1.2. Esophageal metachronous locations
The severity of esophageal metachronous cancer mainly impli-
cates frequently late diagnosis [2], whence in principle the interest
of early screening, if possible at an asymptomatic stage [1,29,30]
when relatively non-invasive curative treatments are feasible: pho-
totherapy, CO2 laser, endoscopic resection [30].
1.2.1. Epidemiology
Mean annual incidence is 2.3% (range, 0.6–4.7%) [31,32]. The
variation in reported incidence is due to differences in sample size
and follow-up time and variable risk factors according to primary
location.
The risk of esophageal cancer after treatment for head and neck
cancer is 15–20-fold greater than in the general population [30].
Time to onset ranges between 1 and 5 years in 58% of cases, 6
and 10 years in 25% and more than 10 years in 17% [1].
The mid-third of the esophagus is the most frequent location
[31], but several others are not exceptional (27.3%) [33].










































racic metastases. If cervical CT is required, the two may
be associated, but with contrast medium injection (expert
opinion).D. Blanchard et al. / European Annals of Otorhinola
.2.2. Clinical alerts
Clinical signs, when present, indicate a stage that is already fairly
dvanced, whence the importance of informing the patient about
larm signals [29].
Dysphagia is the ﬁrst symptom, often in the form of a simple
ensation of food “getting stuck”. It may  be associated with chest
ain.
Impairment of good esophageal voice should also be reported.
.2.3. Means of diagnosis
.2.3.1. Imaging. Barium sulfate contrast transit time, with or with-
ut radiocinematography [34], no longer plays a role in early
iagnosis.
CT and MRI  are contributive only to pre-treatment assessment
nd not to diagnosis.
.2.3.2. Abrasive esophageal cytology [32,35]. Abrasive esophageal
ytology is a frequent means of screening for several teams: notably
n certain Chinese provinces, Iran and South Africa.
It is, nevertheless, no longer recommended except for controlled
rospective clinical studies.
.2.3.3. Fiberoptic endoscopy [30,31]. Fiberoptic endoscopy is indi-
ated:
in ﬁrst-line in case of alarm signs;
secondarily, to complement positive or uncertain esophageal
cytology results in organized screening programs;
in programmed surveillance, for certain teams.
Conventional ﬁberoptic endoscopy is insufﬁcient to diagnose
uperﬁcial cancerous lesions in asymptomatic patients [36].
Videoendoscopy has given a new lease of life to chromoen-
oscopy, which enhances endoscopic diagnostic performance by
elping diagnosis of superﬁcial lesions.
Several stains are available:
methylene blue and indigo carmine are particularly used in
screening for intestinal metaplasia and high-grade dysplasia in
Barrett’s esophagus;
Lugol’s 2% iodine (which has replaced toluidine blue) isolates
abnormal yellowish-white islands within otherwise uniformly
green-brown stained esophageal mucosa, enabling targeted
biopsy [37]; it shows high sensitivity (96%) but poor speciﬁcity
(63%), and fails to stain the glandular mucosa, erosion and inﬂam-
mation or leukokeratosis.
In 2006, Dubuc et al. [36] reported a French prospective multi-
enter study of the contribution of routine screening for neoplastic
nd preneoplastic esophageal lesions in patients considered at risk
f esophageal squamous cell carcinoma but asymptomatic at the
ime of endoscopy. Esophageal ﬁberoptic endoscopy was  usually
erformed under local anesthesia with premedication, ﬁrst under
hite light and then polarized light, 2 to 5 minutes after vaporiza-
ion with 10–20 mL  Lugol 2%. Between September 2000 and June
003, 1095 patients were included, 393 of whom had been previ-
usly treated for head and neck cancer or bronchial squamous cell
arcinoma. Incidence of esophageal cancer was 5.4%.
In 2013, Su et al. [38] reported a retrospective study of 3053
atients followed for head and neck cancer. Those who had under-
one routine screening for esophageal cancer showed signiﬁcantly
igher incidence than those diagnosed only in case of positive
ymptomatology without routine screening: 4.5% vs. 3%; P = 0.4.
oreover, in patients diagnosed on routine endoscopy, early-
tages were signiﬁcantly more frequent: 41% vs. 20%; P = 0.2.logy, Head and Neck diseases 132 (2015) 217–221 219
Finally, recent use of narrow-band imaging (NBI) suggests that
it enhances sensitivity in esophageal ﬁberoptic endoscopy.
In 2009, Kuraoka et al. [39] compared Lugol versus NBI in the
detection of malignant esophageal lesions in 49 patients at risk
of esophageal cancer: chronic alcohol abuse, history of head and
neck cancer. NBI was  performed ahead of Lugol 1.5% vaporization.
Results showed:
• 118 suspect mucosal lesions, including 5 with an aspect of squa-
mous cell carcinoma;
• that carcinoma was systematically positive on NBI and iodine-
negative on Lugol staining;
• not all iodine-negative lesions on Lugol staining were carcinomas.
Sensitivity was  100% for both NBI and Lugol, but speciﬁcity was
59% for NBI and 4.4% for Lugol.
In 2010, Lee et al. [40] assessed the contribution of NBI in
esophageal ﬁberoptic endoscopy in 69 patients treated for head
and neck squamous cell carcinoma. White light examination was
performed ahead of NBI. Twenty-one esophageal neoplasias were
diagnosed (30.4%), including 57.1% multiple lesions and 47.6% early
grade. NBI was more effective than white light in detection: 35
lesions diagnosed in 21 patients (including 13 dysplastic lesions) on
NBI versus 22 in 18 patients (including 3 dysplastic lesions) under
white light. Sensitivity was  62.7% and 100% for white light and NBI,
respectively.
1.2.4. Synthesis
Improved patient survival is directly related to the stage of pro-
gression of the metachronous esophageal tumor.
The only examination able to improve survival is endoscopy
with staining, which detects early-stage lesions. Novel techniques
such as NBI are not presently feasible for routine application and
are available only for controlled prospective studies.
There are no reports in the literature of survival gain with rou-
tine esophageal cancer screening by ﬁberoptic endoscopy with
Lugol staining in head and neck cancer. It is a heavy examina-
tion and prognosis is poor in esophageal cancer; endoscopy cannot
therefore be considered standard but only as an optional examina-
tion.
Large-scale prospective randomized studies will be needed to
assess its contribution, and should be encouraged.
When head and neck endoscopy is performed under gen-
eral anesthesia, esophageal examination can be associated (expert
opinion).
Guidelines for bronchial and esophageal metachronous
tumor screening
• There are no validated biological markers for bronchopul-
monary and esophageal cancer screening (grade A).
• The patient should be informed of the risk of pulmonary
and esophageal second cancer and of the alarm symptoms
(expert opinion).
• Low-dose thoracic CT without contrast enhancement is rec-
ommended in patients who have not quit smoking for at
least 15 years (grade A). This examination also detects tho-• Routine esophageal ﬁberoptic endoscopic screening is only
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. Head and neck cancer and metastasis
.1. Incidence
Mean incidence of metastasis during head and neck cancer
ollow-up is 11.8% (range, 3–20.5%), close to the 11% reported
y Merino in the largest clinical series to date (5019 patients)
29,41–45].
.2. Location and disease type
The most frequently involved organs are, in decreasing order,
he lungs, the bone skeleton and the liver [41–44]. In 80% of cases,
here is a single metastatic site: the lung [44]. Isolated bone or liver
nvolvement is exceptional: the lungs are associated in 97% of cases
42,43].
.3. Time to onset
Ninety-ﬁve percent of metastases are diagnosed within 2 years
f primary diagnosis. Except in a few reports, onset after 3 years is
xceptional [29,41,42,46]. Median time to onset in the ﬁrst location
s 10 months [46].
.4. Factors for onset of metastasis
In 50% of cases, metastases are associated with persistent locore-
ional progression [41,42]. The roles of location, size and histologic
ifferentiation in onset of metastasis remain controversial, but
here is near unanimity as to a signiﬁcant relation between lymph
ode status and incidence of metastasis [41–44,46–48].
Metastasis risk increases in case of [43,48]:
3 cervical nodes (N2b or c);
bilateral metastatic nodes (N2c);
node(s) ≥ 6 cm (N3);
node(s) low in the neck;
≥ 1 capsule rupture and/or lymphatic and perineural emboli on
histology;
and according to histologic type: basaloid squamous cell car-
cinoma (BSCC) is associated with elevated rates of metastasis,
which is the prime cause of mortality in this histologic type, impli-
cated in 45–65% of deaths; the largest clinical case-control series
of BSCC to date was that of Soriano, with 62 patients [49].
.5. Complementary examinations contributive to diagnosis
Lung X-ray is the most frequently prescribed examination for
ung metastasis screening. Sensitivity ranges between 20% and 50%
nd speciﬁcity between 90% and 98% [42,43]. False negatives are
ommon as metastatic pulmonary lesions are usually peripheral,
here lung X-ray is least effective. Thoracic CT is sensitive, but with
oor speciﬁcity of around 30% [46,47,50]: CT detects numerous
odules, but these are not always malignant; they may, for exam-
le correspond to infection sites, especially in case of swallowing
isorder. PET-CT can determine whether a nodule is “metabolically
ctive”, which, in context, may  contribute to diagnosis of metasta-
is. [45]. However, PET-CT fails to distinguish between metastasis
nd infection site, both giving rise to hyperﬁxation. It is, even so,
 very effective means of screening for secondary locations, wher-
ver they may  be situated, with 91% sensitivity and 93% speciﬁcity
45].Isolated nodules of < 1 cm diameter found on CT may  be moni-
ored on CT (at 3 months); in case of progression or > 1 cm nodule,
ET-CT, ﬁne-needle aspiration under CT or surgical exploration may
e considered.logy, Head and Neck diseases 132 (2015) 217–221
Bone metastasis screening is indicated only in case of pain or
hypercalcemia. The basic examinations are plain X-ray and CT, or
MRI. Bone scintigraphy should be prescribed in case of isolated
hypercalcemia. Risk of neural compression in the spine should lead
urgently to specialist (orthopedic or neurosurgical) opinion with a
view to decompression.
In liver metastasis screening, examinations are needed only in
case of clinical signs: hepatalgia, hepatomegaly. Ultrasound is the
ﬁrst-line examination, supplemented if need be by CT.
Biological liver analyses (SGOT, SGPT, alkaline phosphatase,
Gamma  GT, LDH, bilirubin) and alkaline phosphatase assay to
screen respectively for liver and bone metastasis, are non-
contributive, have poor sensitivity and no speciﬁcity [42,43].
Lung metastasis does not systematically require screening for
bone and/or liver metastasis, which should rather be guided by
clinical ﬁndings.
2.6. Synthesis
Only a single lung metastasis can in some cases be associated
with long survival, justifying curative treatment.
Onset of multiple metastases following head and neck cancer
is of poor prognosis, as there is presently no curative attitude. The
interest of screening is therefore questionable. Ferlito et al., in con-
trast, consider metastasis screening to be mandatory in head and
neck cancer, for two reasons: ﬁrstly, the patient and family need
to be informed regarding progression; secondly, screening helps
anticipate:
• the medical complications some metastases induce (compres-
sion, fracture in case of bone metastasis);
• the familial and social consequences of approaching death, the
aim being not curative treatment but a better physical, moral and
social comfort toward the end of life.
A third objective may  be included: to limit investigation in the




• there are no indications for biological analyses to screen for
metastasis (grade A);
• screening for lung, bone and liver metastasis should be
guided by clinical ﬁndings (expert opinion);
• in case of late metastasis (> 3 years) without local recurrence,
a second primary cancer should be looked for (Expert opin-
ion).
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